Sodium-glucose cotransporter 2 inhibitors antagonize lipotoxicity in human myeloid angiogenic cells and ADP-dependent activation in human platelets: potential relevance to prevention of cardiovascular events

BACKGROUND: The clear evidence of cardiovascular benefits in cardiovascular outcome trials of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in type 2 diabetes might suggest an effect on atherosclerotic plaque vulnerability and/or thrombosis, in which myeloid angiogenic cells (MAC) and platelets...

Descripción completa

Detalles Bibliográficos
Autores principales: Spigoni, Valentina, Fantuzzi, Federica, Carubbi, Cecilia, Pozzi, Giulia, Masselli, Elena, Gobbi, Giuliana, Solini, Anna, Bonadonna, Riccardo C., Dei Cas, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140327/
https://www.ncbi.nlm.nih.gov/pubmed/32264868
http://dx.doi.org/10.1186/s12933-020-01016-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140327/
https://www.ncbi.nlm.nih.gov/pubmed/32264868
http://dx.doi.org/10.1186/s12933-020-01016-5

Ejemplares similares